• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    O

    Ospedale Policlinico San Martino,Istituti di Ricovero e Cura a Carattere Scientifico

    EST. 1907
    2,891论文总数
    6.1万引用总数

    论文量&引用量时间轴

    机构学者

    论文(2891)

    年份
    起
    –
    止
    排序
    1Spontaneous Breathing Trials As Predictors of Extubation Outcomes in Neurocritical Care: Insights from the ENIO Study
    Denise Battaglini,Shaurya Taran, Francesca Gualdi,Raphael Cinotti,Karim Asehnoune, Andrea Loggini, Luca Montagnani,Patricia R. M. Rocco, Marcus J. Schultz, Nicolò Antonino Patroniti,Chiara Robba

    In critically ill patients, extubation readiness is typically assessed using a spontaneous breathing trial (SBT). Among patients with acute brain injury (ABI), the optimal SBT method remains uncertain. We conducted a post-hoc analysis of the ENIO study (NCT03400904), including mechanically ventilated ABI patients with available SBT data, undergoing extubation attempt. SBTs were classified as T-piece, pressure support ventilation (PSV), or continuous positive airway pressure (CPAP). The primary outcome was extubation failure within 5 days. Associations between SBT modality and extubation failure were assessed using multivariable logistic regression and inverse probability of treatment weighting. Of 1,512 patients enrolled in ENIO, 839 met the inclusion criteria, of whom 270 (32.2

    2026Intensive Care Medicine(2026)引用:3
    引用
    AI阅读
    加入学术空间
    2Plasma Extracellular Vesicles and Phosphorylated Tau 181 As Early Biomarkers of Cognitive Impairment in Alzheimer’s Dementia
    Viviana Brembati, Daniela Crescenti,Andrea Geviti, Elisa Rossini, Federico Angelo Cazzaniga,Fabio Moda, Elisa R. Zanier,Gisella Guerrera,Luca Battistini,Simone Baiardi,Alessandra Mandelli, Roberto Furlan,

    Timely and accurate diagnosis of Alzheimer’s disease (AD) in clinical practice is a great challenge, especially during early disease stages with subtle or mild symptoms of cognitive decline. Moreover, robust and more accessible blood-based screening tests for early diagnosis are needed. In this study, we investigated the core AD blood biomarkers — amyloid beta 42 (Aβ42) and 40 (Aβ40) peptides, phosphorylated tau 181 (p-Tau181), neurofilament light chain (NfL), and total tau (t-Tau) — and extracellular vesicle (EVs) size and concentration in individuals characterized by different stages of cognitive decline to identify biochemical markers of dementia for early diagnosis. A total of n = 800 human plasma samples were analyzed. Plasma levels of NfL, t-Tau, p-Tau181, Aβ42, Aβ40 and plasma EVs were evaluated in n = 217 elderly healthy subjects (CTRL), in individuals with subjective cognitive complaints (SCC, n = 48), pre-mild cognitive impairment (pre-MCI, n = 58) and mild cognitive impairment (MCI, n = 426), and in n = 51 probable AD dementia patients (AD-dem), using ultrasensitive Single Molecule Array technology (Simoa®) and nanoparticle tracking analysis (NTA). Logistic regression and Receiver Operating Characteristic (ROC) analyses were employed. Plasma NfL displayed increased levels in AD-dem and MCI patients, while p-Tau181, Aβ42/Aβ40 ratio, Aβ42/p-Tau181 ratio, and EVs plasma levels were altered since the early stages of the pathology: in particular, p-Tau181 levels increased as cognitive symptoms worsened, already in the SCC and pre-MCI groups compared to CTRL, while the ratio of EVs concentration and size (EVs ratio) was decreased in all groups compared to CTRL. Plasma p-Tau181 best classified AD-dem patients from CTRL with an area under the curve (AUC) equal to 0.87, while EVs ratio best differentiated SCC from CTRL (AUC = 0.78). Combining p-Tau181 and EVs ratio with Aβ42/Aβ40 ratio and NfL, respectively, significantly improved the classification of pre-MCI and MCI from CTRL (AUCcomb = 0.79 and AUCcomb = 0.85). Combining biomarkers did not improve accuracy in discriminating MCI from SCC, pre-MCI and AD-dem. p-Tau181 and EVs ratio are promising biomarkers for the identification of individuals at risk of degenerative dementia. Combining the core AD plasma biomarkers with EVs ratio can aid in diagnosing the early stages of AD dementia.

    2026Alzheimer's Research & Therapy(2026)引用:2
    引用
    AI阅读
    加入学术空间
    3Best Therapeutic Approach in Metastatic Hormone-Sensitive Prostate Cancer Based on Disease Volume: a Systematic Review and Network Meta-Analysis.
    Fabrizio Di Costanzo,Chiara Mercinelli,Alessio Signori,Carlo Messina,Vincenza Conteduca, Giovanni Dima,Matteo Santoni, Luigi Formisano,Christoph Oing,Giuseppe Fornarini,Sara Elena Rebuzzi,Orazio Caffo,

    CONTEXT:With new treatment strategies approved in metastatic hormone-sensitive prostate cancer (mHSPC), heterogeneity across trials hinders the physicians' choice for first-line treatment. OBJECTIVE:We conducted a systematic review and network meta-analysis to assess the efficacy of currently approved treatments for mHSPC stratifying patients according to their disease burden (high- vs. low-volume as per CHAARTED criteria) and onset of metastatic disease (synchronous vs. metachronous). INTERVENTION:Eleven randomized controlled trials (RCTs) published until October 30, 2024 were included. Treatment regimens were grouped as triplets for combinations of docetaxel, androgen receptor pathway inhibitors (ARPIs) and androgen-deprivation therapy (ADT), separate doublets for docetaxel plus ADT, ARPI plus ADT, or monotherapy for ADT alone. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS:Overall survival (OS) and radiographic progression-free survival (rPFS) outcomes were collected. OS as primary endpoint, and rPFS as secondary endpoint, were analyzed separately in high- and low-volume patients. Additional subgroup analyses accounted for timing of metastases categorized as high-volume/synchronous, high-volume/metachronous, low-volume/synchronous, and low-volume/metachronous disease. EVIDENCE SYNTHESIS:Triplet combinations prolonged significantly OS and rPFS in high-volume disease (P-score 0.99), and high-volume/synchronous disease (P-score 0.99). ARPI/ADT doublets performed best in low-volume patients (P-score 0.94), and low-volume/metachronous (P-score 0.99). In the high-volume/metachronous population, triplets, and doublets were equally effective. CONCLUSIONS:The results provide collective evidence for treatment selection based on disease volume and timing of metastasis with strongest survival benefits of triplets for high-volume/synchronous mHSPC patients and of ARPI doublets for low-volume disease.

    2026The oncologist(2026)引用:1
    引用
    AI阅读
    加入学术空间
    4A Phase II, Open-Label Study to Improve Compliance and Time of Treatment after Obtaining Complete Response (CR) Through a Tailored Schedule of Sonidegib in Locally Advanced Basal Cell Carcinomas (labcc): the SONIBEC Trial.
    Carlo Resteghini, Monica Variolo,Sara Farinatti,Andrea Alberti,Valeria Tovazzi,Paola Queirolo,Maristella Saponara,Giuseppe Agenziano,Riccardo Marconcini,Ketty Peris,Paola Savoia,Maria Chiara Tronconi,

    9540 Background: Sonidegib is an efficacious treatment of LA laBCC but is associated with a high risk of treatment-related adverse events (TRAEs) causing treatment discontinuation. Following a CR, treatment discontinuation rate reaches up to 60% after a year, leading to 3 years relapse free survival rate of 35%. We aimed at evaluating sonidegib tailored schedule (TS) after CR to increase treatment duration by reducing TRAEs, thus allowing CR maintenance. Methods: We conducted a multicenter, open-label, single-arm phase II study enrolling adult patients (pts) with laBCC who obtained a CR to sonidegib regardless of the tumor’s subtype and burden. Eligible pts received TS1 with sonidegib 14 days on and 14 days off. Pts on TS1 who experienced grade 2-3 toxicity (except alopecia) lasting >28 days moved to TS2 (7 days on and 21 days off). Treatment continued until progression or unacceptable toxicity. Primary endpoint was the rate of pts maintaining sonidegib 12 months after study enrolment (H0 31%, H1 60%). Evaluable pts were defined as all pts who were either on treatment or suspended treatment for reasons other than treatment-unrelated adverse events or death. Secondary endpoints were safety, treatment compliance, rate of disease relapse at 1 and 2 years, overall survival, quality of life, use of concomitant medications and of medical resources, and translational analysis. Results: Between Jan 2021 and Dec 2023, 22 pts from 10 Italian centers were enrolled; the data cut-off was Jan 2025. Pts characteristics are reported in table 1. The median follow-up was 22 months (range 2-33). Three disease and treatment-unrelated deaths occurred before completing 1 year of TS and therefore 19 pts were evaluable. At data cut-off, 12 pts had discontinued treatment: 26% (5) due to disease progression, 11% (2) to sonidegib’s unacceptable toxicity, the remaining either to personal or physician’s choice. Twelve out of 19 evaluable pts (63%) were still on treatment after 1 year from TS start (median duration 20 months, range 2-29), meeting the primary endpoint. The most common TRAEs episodes were muscle cramps (13), alopecia (6), dysgeusia (5) with overall TRAEs grade G1 (29), G2 (11), G3 (3). Twelve pts had dose reduction to TS2. Conclusions: Tailored maintenance schedule with pulsed sonidegib allows for longer treatment duration and fewer relapses in CR laBCC pts. Study follow up to evaluate secondary endpoints outcome and translational analysis are ongoing. Clinical trial information: 2020-002613-17 . Patient characteristics. Characteristic N (%) Male : Female 14 (64) : 8 (36) Median age 76y (range 56-93y) ECOG PS 0-1 15 (68): 7 (32) Histology sub-type Nodular 8 (36) Superficial 2 (9) Infiltrative 7 (32) Mixed 1 (5) Other 4 (18)

    2026EJC SKIN CANCER(2026)引用:1
    引用
    AI阅读
    加入学术空间
    5Chronic Rhinosinusitis Optimisation of Nasal Outcomes and Scores (CHRONOS): an Italian Delphi Consensus on Long-Term Management with Biologics
    Eugenio De Corso, Frank Rikki Mauritz Canevari,Marco Caminati,Carlotta Pipolo,Enrico Heffler, Matteo Lazzeroni,Veronica Seccia,Massimiliano Garzaro,Giancarlo Ottaviano,Elena Cantone,Fabio Pagella, Giulia Gramellini,

    This review synthesizes current evidence and expert consensus on the long-term management of severe chronic rhinosinusitis with nasal polyps (CRSwNP) treated with biologics, as established by the Italian CHRONOS project. Accumulating real-world and clinical trial data confirm the sustained efficacy and safety of biologics targeting type 2 inflammation, enabling durable control and remission in a significant proportion of patients. Personalized dosing regimens, including dose-spacing strategies, appear feasible. The CHRONOS project provides practical guidance for optimizing long-term biologic therapy in severe CRSwNP. Response assessment should combine subjective and objective measures, especially for olfactory testing. Biologics may be considered before surgery only in selected complex cases. Dose-spacing strategies may be appropriate in stable patients but require multidisciplinary oversight in those with comorbid asthma. Adverse events are uncommon. The concept of disease modification is endorsed, recognizing biologics’ potential to alter the natural history of CRSwNP.

    2026Current Allergy and Asthma Reports(2026)引用:1
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 2891 篇论文

    合作机构(98)

    热那亚大学合作论文 688
    意大利科学领域恢复与治疗研究所合作论文 233
    都灵大学合作论文 184
    罗马大学合作论文 167
    那不勒斯费德里克二世大学合作论文 126
    米兰大学合作论文 120
    佛罗伦萨大学合作论文 117
    帕多瓦大学合作论文 114
    博洛尼亚大学合作论文 101
    巴里阿尔多·莫罗大学合作论文 94

    机构统计